AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Resignation of Director 5 Oct - Krishnakumar Vaidyanathan resigns as Executive Director and COO effective September 30, 2026.
Source: Bse
Eris Lifesciences Limited (ERIS)
Large CapPharma stocks · Large cap · NSE
Eris Lifesciences is a top-20 Indian pharma company, youngest on the list, with 80% revenue from super-specialty segments. It holds a top-5 position in Anti-Diabetes (6% market share) and leads in Insulins (16% share). International business contributed 11% to FY26 consolidated revenue. It has a ~65-member R&D team and 6 globally accredited manufacturing facilities.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals14 Oct 2026 · screener
Latest result29 Jul, 06:43 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
53Neutralfull bear SMA stack · SMA20 -9.7% / mo · RSI oversold · MACD − · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
ERISD candles · FIT view-16.3%Latest close ₹1136.30 on 2026-10-21
Bar
+1.4%
RSI
28
MACD hist
-0.95
52W pos
4%
2026-10-21O ₹1120.40H ₹1149.90L ₹1112.90C ₹1136.30Vol 84,960 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ERISNifty PharmaNifty 500
- ERIS
- -22.7%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -16.2 pp
Chart stats
21 Oct 2026- From 52W high
- -34.7%
- 52W range position
- 4%
- ATR (14)
- 3.2%
- Volume vs 20D
- 0.67x
- Avg traded value
- ₹15.2 Cr
- 20D price channel
- ₹1,111.1 - ₹1,300
₹1,740
₹1,111.1 - ₹1,740
₹36
Latest completed session
20-session average
19.7% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE55
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average42
Revenue +12.9% · PAT +14.4% YoY
Technical
Neutral53
Price trend and sector-relative-strength timing.
Valuation
Legacy model+46.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence81
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 42/100margin compression · Rev +13% YoY · PAT +14% YoY · +15% QoQ
Filed 29 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹873 Cr | +12.9% | +15.3% |
| EBITDA | ₹296 Cr | +6.9% | +8.8% |
| Operating margin | 34.0% | -200 bps | -200 bps |
| PAT | ₹143 Cr | +14.4% | -48.8% |
| PAT margin | 16.4% | +21 bps | -2048 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 24.50
- P/B
- 4.10
- EV/EBITDA
- 12.96
- Market Cap
- 16035.00Cr
Profitability
- ROE
- 18.70%
- ROCE
- 14.10%
- ROA
- 9.35%
- Dividend Y
- 0.63%
Growth (CAGR)
- Revenue 5Y
- 21.00%
- EPS 5Y
- 12.00%
- Revenue 3Y
- 23.00%
- EPS 3Y
- 19.00%
Balance Sheet
- Debt/Equity
- 0.60
- Interest Coverage
- 5.96×
- Altman Z
- 4.93
- Book Value
- 282.00
Cash Flow
- FCF Yield
- 1.05%
- FCF Positive Y
- 8/5
- OCF
- 538.00 Cr
- EPS TTM
- 46.75
Shareholding
- Promoter Hold
- 54.14%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 3%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 873+15.3% vs prev
Net Profit
₹ CrLatest: 143-48.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 28. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~10.8% over last month) — short-term momentum negative.
- RSI(14) at 28 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
14
RS percentile
Stage 4 Downtrend
1M return
-12.3%
3M return
-22.7%
6M return
-18.6%
1Y return
-30.3%
RS 1D
+3
RS 20D
-6
Sector rank
#2
Industry rank
#3
Stage evidence
- Price is 15.8% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.5%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 74.98+2.38%
RS vs Nifty 50075
Valuation & peers
U-Score 55 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 55 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation11/30
Growth15/25
Quality11/20
Balance Sheet7/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
55
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
55/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 46.0%.
- Growth contributes 15/25 to the score.
Main drags
- Valuation is weaker at 11/30; verify the latest quarterly trend.
- Balance sheet is weaker at 7/15; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
24.5
PB
4.1
EV/EBITDA
13.0
ROE
18.7%
ROCE
14.1%
FCF Yield
1.1%
Debt/Equity
0.6
MoS
+46.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
55
Previous: 55
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+46.0%
Previous: +46.7%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
55
55
55
55
55
55
55
55
55
55
55
55
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹544.64
-108.6% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹2,103.75
+46.0% MoS
PEG
1.66
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
CAPLIPOINT
Large
Caplin Point Laboratories Limited
Pharmaceuticals
match 167
61
26.3
20.9%
+43%
UNDERVALUED
ALIVUS
Large
Alivus Life Sciences Limited
Pharmaceuticals
match 165
29
43.7
—
+14%
OVERVALUED
PFIZER
Large
Pfizer Limited
Pharmaceuticals
match 165
33
117.0
19.8%
-738%
WATCHLIST
ASTRAZEN
Small
AstraZeneca Pharma India Limited
Pharmaceuticals
match 160
43
85.2
23.3%
-98%
WATCHLIST
APLLTD
Mid
Alembic Pharmaceuticals Limited
Pharmaceuticals
match 160
34
20.8
13.4%
-453%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-07-13T00:41:19.872Z
Management commentary snapshot
Eris Lifesciences reported robust FY26 financials with revenue up 8.1% YoY to INR 3,129 Cr and EBITDA up 10.1% YoY to INR 1,120 Cr, expanding EBITDA margin to 35.8%. PAT surged 72.8% YoY to INR 648 Cr, aided by a one-off deferred tax adjustment.
The company demonstrates strong execution in domestic branded formulations, particularly with successful new product launches like Gx Semaglutide. Margin expansion and strategic acquisitions have bolstered its therapeutic footprint. While EU-GMP observations pose a near-term delay for CDMO, the core business remains robust with clear growth drivers and capacity expansion plans.
Current business mix
Revenue by Therapy (MAT Mar'26)
Latest issuer-disclosed distribution across 12 reported categories.
Oral Anti-diabetes21.0%
CVD16.0%
CNS13.0%
WHC12.0%
Derma5.0%
Critical Care4.0%
Nephro4.0%
Gastro4.0%
Insulins + GLP-13.0%
ONCO2.0%
VMN3.0%
Rest13.0%
Growth engines
Gx Semaglutide Launch
Strong start with Sundae ranked #1 by sale volume (22%) and #2 by sale value (13%) in Apr'26.
Insulin Analogues & GLP-1 Pipeline
Pipeline includes Degludec, Aspart, and Semaglutide (recombinant) with Phase-I/III trials.
Small Molecule Pipeline
Pipeline of 30+ active candidates, including innovative FDCs and first-to-market products.
International Business Expansion
Presence in 70+ countries, ANVISA approval for Brazil market launch, and foray into EU via Specialty CDMO.
Capacity and execution
Sundae Pens Manufacturing
Phase-I capacity of ~5 mn units p.a. for in-sourcing, expected Q2 FY27.
Biologics Liquid Cartridges
For Insulins/GLP-1, to be commissioned from July-26.
MABs Fill-Finish
Under installation (Liquid/Lyo Vials and Prefilled Syringes), to be commissioned by Dec '26.
General Injectables (Unit-3)
Under construction, planned commissioning in Q1 FY28.
Tailwinds
Gx Semaglutide Market Evolution
Market size and structure for Semaglutide evolving in line with company guidance.
In-sourcing of Sundae Pens
Expected to start in Q2 FY27, leading to significant margin improvement.
Headwinds
EU-GMP Inspection Observations
Procedural non-compliance observations received in April '26.
Delayed EU-CDMO Commercialization
EU-GMP observations will delay commercialization of EU-CDMO product pipeline.
Risk radar
Regulatory Compliance
Non-compliance observations from EU regulatory agency for injectable facilities.
Competition in Key Therapies
Increasing competition in the pharmaceutical industry, especially in new launches like Gx Semaglutide.
Acquisition Integration
Total investment of INR 4,300+ Cr in acquisitions over FY23-FY26, requiring successful integration.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
Annual financial results (FY26 vs FY25) provide a comprehensive view of overall performance and margin trends. Monthly data for new product launches (Gx Semaglutide) is crucial for assessing sequential momentum and market penetration in a rapidly evolving segment.
Sector KPIs management disclosed
Domestic Formulations Growth
FY27 growth guidance is 1.3x of Covered Market (CVM) growth.
International Business Revenue Contribution
Comprised 11% of consolidated revenue in FY26.
International Business Growth
FY27 revenue growth guidance for existing business is 18-20%.
R&D Team Size
State-of-the-art R&D Center with a ~65-member team.
Management forward view
Insulin Market Share Target
Objective to achieve 25% market share in Insulin+Glargine.
Domestic Formulations Growth Outlook
FY27 revenue growth guidance of 1.3x of CVM growth.
Domestic Formulations Margin Outlook
FY27 EBITDA margin expected to be 37%, similar to FY26, with H2 margin higher than H1.
International Business Growth Outlook
FY27 revenue growth guidance for existing business is 18-20%, with EBITDA margin similar to FY26.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| DBF Revenue Growth | FY27 guidance 1.3x CVM growth. | Actual growth relative to CVM and management's target. |
| DBF EBITDA Margin | FY26 35.8%, FY27 guidance 37%. | Sustained margin expansion, especially in H2 FY27. |
| Insulin+Glargine Market Share | 16% in Apr'26. | Progress towards the 25% market share objective. |
| EU-CDMO Commercialization | Delayed due to EU-GMP observations. | Resolution of observations and timeline for product commercialization. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
81Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 93rd percentile of the scored universe and 90th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 21 Oct 2026
management-trust-v1
109 docs text-extracted · 23 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
93rd percentile
overall median 67 · Pharma: 90th pctile, median 70 · Large: 82nd pctile, median 73
Evidence depth
Financial-only
109 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.1%.
- ▸8 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Eris Lifesciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 Sep - Eris Lifesciences schedules in-person 1x1 meeting with Bank of India Mutual Fund on 10 Sept 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Resignation of Director 11 Sep - Executive Director and COO Krishnakumar Vaidyanathan resigns; relieved effective 30 September 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Allotment 22 Sep - Eris Lifesciences allotted 1,55,264 equity shares under ESOP-2021 on 22 September 2026.
Source: Bse
Announcement
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Term Loan From Axis Bank 9 Sep - Eris Lifesciences avails ₹45 crore term loan from Axis Bank to meet liabilities.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Working Capital Term Loan From Axis Bank 6 Aug - Eris Lifesciences drew ₹64.4 crore working capital term loan from Axis Bank on 5 August 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Aug - Eris Lifesciences to meet Franklin Templeton virtually on 14 Aug 2026 at 11:00 AM IST.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Aug
Source: Bse
Concall transcript
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 4 Aug
Source: Bse
Investor presentationJul 2026
Jul 2026 · PPT
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Jul
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.